Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 Predictors of In-Hospital Death in Patients with Lung Cancer Admitted for Acute Radiation Pneumonitis: A Healthcare Cost and Utilization Project (HCUP) Analysis.  Clinical Lung Cancer.  22:e716-e722. 2021
2021 Nonoperative Treatment of Large (5-7 cm), Node-Negative Non-Small Cell Lung Cancer Commonly Deviates From NCCN Guidelines. 2021
2021 Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538.  Lung Cancer.  156:68-71. 2021
2021 Lipid microsphere bound oxycodone for pain management in patients receiving radiotherapy for head and neck cancer.  Supportive Care in Cancer.  29:263-269. 2021
2020 Anchored Transponder Guided Lung Radiation Therapy.  Practical Radiation Oncology.  10:e37-e44. 2020
2019 Electromagnetic Transponder Based Tracking and Gating in the Radiotherapeutic Treatment of Thoracic Malignancies.  Practical Radiation Oncology.  9:456-464. 2019
2019 Longitudinal assessment of anchored transponder migration following lung stereotactic body radiation therapy.  Journal of Applied Clinical Medical Physics.  20:17-22. 2019
2019 Non-small cell lung cancer, version 1.2020: Featured updates to the NCCN guidelines 2019
2018 NCCN guidelines® insights: Small cell lung cancer, version 2.2018 featured updates to the NCCN guidelines 2018
2018 NCCN guidelines ® insights non–small cell lung cancer, version 5.2018 featured updates to the NCCN guidelines 2018
2018 Stereotactic Radiosurgery for Prostate Cancer Following Magnetic Resonance Imaging Directed Biopsy: A Multidisciplinary Approach with Case Examples..  Cureus.  10:e2524. 2018
2017 Subcutaneous adipose tissue characteristics and the risk of biochemical recurrence in men with high-risk prostate cancer.  Urologic Oncology: Seminars and Original Investigations.  35:663.e15-663.e21. 2017
2017 Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology 2017
2017 Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: A secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial.  Journal of Clinical Oncology.  35:56-62. 2017
2016 Analysis of Predictive Factors for Acute Esophagitis in Lung Cancer Radiation Therapy. 2016
2016 Analysis of Predictive Factors for Pneumonitis in Lung Cancer Radiation Therapy. 2016
2016 Correction: Kinomic profiling of electromagnetic navigational bronchoscopy specimens: A new approach for personalized medicine (PLoS ONE (2016) 9:12 (e116388) DOI: 10.1371/journal.pone.0116388).  PLoS ONE.  11. 2016
2016 NCCN Guidelines®: Insights malignant pleural mesothelioma, version 3.2016 2016
2016 NCCN guidelines® Insights: Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines 2016
2016 Long-term outcomes among patients who achieve complete or near-complete responses after the induction phase of bladder-preserving combined-modality therapy for muscle-invasive bladder cancer: A pooled analysis of NRG Oncology/RTOG 9906 and 0233 2016
2015 Non-Small Cell Lung Cancer, Version 6.2015. 2015
2015 Non-Small cell lung cancer, version 6.2015: Featured updates to the NCCN guidelines 2015
2015 A phase 3 trial of 2 years of androgen suppression and radiation therapy with or without adjuvant chemotherapy for high-risk prostate cancer: Final results of radiation therapy oncology group phase 3 randomized trial NRG oncology RTOG 9902 2015
2015 Continuous chemoradiation following complete response to neo-adjuvant chemotherapy provides improved outcomes in muscle invasive urothelial carcinoma.  Journal of Solid Tumors.  5:59-68. 2015
2015 Retention rate of electromagnetic navigation bronchoscopic placed fiducial markers for lung radiosurgery.  Annals of Thoracic Surgery.  100:1163-1166. 2015
2014 Kinomic profiling of electromagnetic navigational bronchoscopy specimens: A new approach for personalized medicine.  PLoS ONE.  9. 2014
2014 Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide.  Radiation Oncology.  9. 2014
2014 Comparison of plan quality and delivery time between volumetric arc therapy (rapidarc) and gamma knife radiosurgery for multiple cranial metastases.  Neurosurgery.  75:409-417. 2014
2014 PSA response to neoadjuvant androgen deprivation is an independent prognostic marker and may identify patients who benefit from treatment escalation.  Urologic Oncology: Seminars and Original Investigations.  32:687-693. 2014
2013 Effects of flattening filter-free and volumetric-modulated arc therapy delivery on treatment efficiency..  Journal of Applied Clinical Medical Physics.  14:4328. 2013
2013 Stereotactic body radiation therapy (SBRT) for lung malignancies: Preliminary toxicity results using a flattening filter-free linear accelerator operating at 2400 monitor units per minute.  Radiation Oncology.  8. 2013
2013 Patient benefit from salvage radiation for prostate cancer..  Journal of Clinical Oncology.  31:175. 2013
2013 Effects of flattening filter-free and volumetric-modulated arc therapy delivery on treatment efficiency.  Journal of Applied Clinical Medical Physics.  14:155-166. 2013
2013 Flattening filter-free linac improves treatment delivery efficiency in stereotactic body radiation therapy.  Journal of Applied Clinical Medical Physics.  14:4126. 2013
2013 Flattening filter-free linac improves treatment delivery efficiency in stereotactic body radiation therapy.  Journal of Applied Clinical Medical Physics.  14:64-71. 2013
2013 Optimal planning target volume margins for elective pelvic lymphatic radiotherapy in high-risk prostate cancer patients..  ISRN Oncology.  2013:941269. 2013
2012 Hypofractionated Prostate Radiotherapy with or without Conventionally Fractionated Nodal Irradiation: Clinical Toxicity Observations and Retrospective Daily Dosimetry..  Prostate Cancer.  2012:546794. 2012
2011 Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation.  Radiotherapy and Oncology.  101:183-189. 2011
2011 Cetuximab augments cytotoxicity with poly (ADP-Ribose) polymerase inhibition in head and neck cancer.  PLoS ONE.  6. 2011
2011 Efficacy and rectal toxicity of hypofractionated radiation therapy with daily image guidance..  Journal of Clinical Oncology.  29:85. 2011
2011 Dosimetric analysis of imaging changes following pulmonary stereotactic body radiation therapy 2011
2011 Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide 2011
2010 Margin on Gross Tumor Volume and Risk of Local Recurrence in Head-and-Neck Cancer 2010
2009 Cancer of the tonsil presenting as central nervous system metastasis: A case report 2009
2006 Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: A phase I study 2006

Principal Investigator On

Investigator On

  • A Phase II Study of Durvalumab (MEDI 4736) with Radiotherapy for the adjuvant treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma  awarded by University of North Carolina at Chapel Hill
  • A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer  awarded by University of Florida
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • Markers of Cardiotoxicity with Radiation Therapy in Breast Cancer  awarded by University of Pennsylvania
  • Markers of Cardiotoxicity with Radiation Therapy in Breast Cancer-Fixed Price  awarded by University of Pennsylvania
  • NRG Oncology Member Institution Clinical Trial Fixed Price Subaward Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • ONE SHOT - Single Shot Radiotherapy for Localized Prostate Cancer - A Multicenter, Single Arm, Phase I/II Trial  awarded by GENEVA UNIVERSITY HOSPITAL
  • Pragmatic Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial  awarded by University of Pennsylvania
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by ABBOTT LABORATORIES
  • Private Grant  awarded by SPECTRUM PHARMACEUTICALS, INC.
  • Private Grant  awarded by VARIAN MEDICAL SYSTEMS, INC.
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by SUCAMPO PHARMACEUTICALS
  • Private Grant  awarded by NOVOCURE, INC.
  • Private Grant  awarded by VARIAN MEDICAL SYSTEMS, INC.
  • Private Grant  awarded by VARIAN MEDICAL SYSTEMS, INC.
  • Private Grant  awarded by VARIAN MEDICAL SYSTEMS, INC.
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • RTOG Foundation Master Service Agreement for Participation in Foundation Research: RTOG 3501 Tryhard: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb) for Non-HPV Locally Advanced Head and Neck Cancer with Concurrent Chemoradiation  awarded by American College of Radiology
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION

    • Education And Training

  • Mercy St. Vincent Medical Center, Internship
  • UAB Hospital, Residency
  • Doctor of Medicine, Medical College of Ohio 2002

    • Full Name

  • Michael Dobelbower